期刊
CURRENT OPINION IN IMMUNOLOGY
卷 65, 期 -, 页码 50-56出版社
CURRENT BIOLOGY LTD
DOI: 10.1016/j.coi.2020.03.013
关键词
-
类别
资金
- National Institute of Allergy and Infectious Diseases [P01 AI110657, R01 AI13662]
- Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery [UM1 AI144462]
- International AIDS Vaccine Initiative Neutralizing Antibody Center
- Bill and Melinda Gates Foundation CAVD [OPP1115782, OPP1084519, OPP1170236]
- NIAID Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract [75N93019C00051]
The recent explosion of atomic-level structures of glycoproteins that comprise the surface antigens of human enveloped viruses, such as RSV, influenza, and HIV, provide tremendous opportunities for rational, structure-based vaccine design. Several concepts in structure-based vaccine design have been put into practice and are are well along preclinical and clinical implementation. Testing of these designed immunogens will provide key insights into the ability to induce the desired immune responses, namely neutralizing antibodies. Many of these immunogens in human clinical trials represent only the first wave of designs and will likely require continued tweaking and elaboration to achieve the ultimate goal of enhanced breadth and potency. Considerable effort is now being invested in germline targeting, epitope focusing, and improved immune presentation such as multivalent nanoparticle incorporation. This review highlights some of the recent advances in these areas as we prepare for the next generation of immunogens for subsequent rounds of iterative vaccine development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据